DAI-NIPPON-PRINTING
16.12.2020 07:08:08 CET | Business Wire | Press release
Amid increased awareness of hygiene and safety as the Covid-19 pandemic continues to spread around the world, Dai Nippon Printing Co., Ltd. (DNP) (TOKYO: 7912) has developed a new transparent display screen that can be operated in a touchless format, by merely moving a hand over a motion sensor. By removing the need to make direct contact with the cursor, the newly developed screen will be positioned as a countermeasure to the spread of Covid-19.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201215006213/en/
https://www.youtube.com/watch?v=h5QKhThRtWw
A liquid crystal (LC) light control film is attached to a transparent screen facilitating a variety of video expressions on a single screen, from standard displays to augmented reality (AR) driven effects, including those where vivid images appear to hang in the air.
For further information about LC light control film, please visit:
https://www.dnp.co.jp/eng/news/detail/1191596_2453.html
For further information about transparent screens that can be used in bright location please visit:
https://www.dnp.co.jp/eng/news/detail/10158931_2453.html
.
[Background]
As health and safety awareness grows, more users are calling for the development of products with antibacterial and antiviral functions, along with those that can be used in a touchless format.
At the same time, we have also recently seen a heightened focus on AR technology that supports consumer activities by imposing artificially created information over existing real world information. In answer to these dual developments, DNP has created a touchless display screen capable of giving expression to AR-driven spatial effects that enhance the immersive impact of presentations.
This has been achieved through the successful combination of, 1, a motion sensor that detects the operator’s movements, 2, an LC light control film that produces a clear image, and 3, a transparent screen that heightens the AR effect.
[Display Features]
- The in-built motion sensor detects the movements of users and operators, and by activating the LC light control film, which is integrated into the transparent screen, makes it possible to display clearer images.
- Bringing the palm of the hand closer to the screen activates the sensor, which causes the cursor to appear. The cursor can then be maneuvered in a touchless format via hand movements, including clicking on screen buttons to set actions into motion by bending the index finger towards the screen.
- DNP’s proprietary LC light control film leverages coating technology to achieve a precise coating of the LC. And, by controlling the direction of the LC using electrical power, it is possible to block or transmit light with high precision, enabling the display of diverse and clear images.
- The DNP transparent screen is produced by applying a precision lens to a large film substrate using advanced optical lens design technology and fine shaping technology.
- The background can be viewed by making the integrated LC light control film transparent then projecting an image upon it. In this way, it is possible to achieve an AR effect in which images appear to hand in the air.
[Looking Ahead]
We anticipate a variety of usage scenarios for the touchless transparent screen, such as in vending and ticket machines, along with uses as the reception desks at hotels and companies. In addition, DNP will further develop and propose LC light control films and transparent screens targeting touchless displays as a countermeasure against infectious diseases.
[About DNP]
DNP is one of the world’s largest comprehensive printing companies, providing a diverse portfolio of products and services to about 20,000 corporate clients worldwide. Since we were founded in 1876, we have consistently innovated new products and processes, and have successfully integrated proprietary printing and information technologies to branch out into various fields, including packaging, decorative materials, display components, and electronic devices. DNP continues to take on the challenge of new business fields, including those related to the environment, energy, and life sciences. Our aim is to become a principal provider of solutions to a variety of problems by developing and combining new technologies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201215006213/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
